Bivariable analysis of baseline characteristics of 703 study participants aged > 50 years and living with HIV included in the final analysis stratified by new-onset diabetes during follow-up
| New-onset diabetes (n=132) | No diabetes (n=571) | P value | |
| Sex at birth; n (%) | |||
| Male | 120 (19) | 502 (81) | 0.368 |
| Female | 12 (15) | 69 (85) | |
| Ethnicity; n (%) | |||
| Asian | 14 (28) | 36 (72) | 0.132 |
| Black | 5 (21) | 19 (79) | 0.793 |
| Indigenous | 20 (25) | 61 (75) | 0.177 |
| Hispanic | 9 (29) | 22 (71) | 0.161 |
| White | 92 (18) | 423 (82) | 0.126 |
| History of IDU; n (%) | |||
| Yes | 53 (20) | 215 (80) | 0.620 |
| No | 79 (18) | 356 (82) | |
| Heterosexual; n (%) | |||
| Yes | 65 (21) | 239 (79) | 0.112 |
| No | 61 (16) | 312 (84) | |
| Homosexual/bisexual; n (%) | |||
| Yes | 59 (17) | 288 (83) | 0.279 |
| No | 67 (20) | 263 (80) | |
| HCV antibody positive; n (%) | |||
| Yes | 64 (21) | 235 (79) | 0.144 |
| No | 68 (17) | 333 (83) | |
| HBV surface antigen positive; n (%) | |||
| Yes | 11 (20) | 43 (80) | 0.720 |
| No | 107 (19) | 462 (81) | |
| AIDS-defining illness at the end of follow-up; n (%) | |||
| Yes | 44 (20) | 177 (80) | 0.604 |
| No | 88 (18) | 394 (82) | |
| Calendar year of first ART; n (%) | |||
| 1997–1999 | 60 (30) | 140 (70) | <0.001 |
| 2000–2004 | 51 (27) | 137 (73) | |
| 2005–2009 | 19 (9) | 182 (91) | |
| 2010–2015 | 2 (2) | 112 (98) | |
| Main class of first ART regimen; n (%) | |||
| NNRTI | 30 (15) | 172 (85) | 0.003 |
| PI | 86 (19) | 374 (81) | |
| Others | 16 (39) | 25 (61) | |
| Age at HIV diagnosis, years; n (%) | |||
| <50 | 93 (19) | 407 (81) | 0.832 |
| ≥50 | 39 (19) | 164 (81) | |
| Age at ART initiation, years; n (%) | |||
| <50 | 88 (20) | 362 (80) | 0.546 |
| ≥50 | 44 (17) | 209 (83) | |
| Latest weight during follow-up (kg); median (Q1–Q3) | 73 (66–86) | 72 (63–84) | 0.122 |
| Latest BMI during follow-up (kg/m2); median (Q1–Q3) | 25 (22–28) | 24 (21–27) | 0.161 |
| Latest hemoglobin during follow-up (g/dL); median (Q1–Q3) | 145 (130–157) | 142 (132–152) | 0.201 |
| CD4 nadir (cells/mm3); median (Q1–Q3) | 80 (21–150) | 130 (40–230) | <0.001 |
| CD4 count at ART initiation (cells/mm3); median (Q1–Q3) | 180 (70–340) | 240 (120–370) | 0.016 |
| Deceased as of 31 July 2015; n(%) | |||
| Yes | 20 (21) | 74 (79) | 0.481 |
| No | 112 (18) | 497 (82) |
Ethnic groups are not mutually exclusive and were unknown in some cases. Other first classes of ART regimen: NRTI only including zidovudine/lamivudine, stavudine/lamivudine, or other NRTI-only regimen (n=33; 80%) and regimens including both an NNRTI and a PI (n=8; 20%).
ART, antiretroviral therapy; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; IDU, injection drug use; NNRTI, non-nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; Q1–Q3, 25th and 75th percentile.